Drug Profile
AMC 303
Alternative Names: AMC-303; HP-558Latest Information Update: 28 Dec 2022
Price :
$50
*
At a glance
- Originator amcure
- Developer amcure; Hinova pharmaceuticals
- Class Antineoplastics; Peptides
- Mechanism of Action CD44 antigen inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Oesophageal cancer
- Phase I Solid tumours
Most Recent Events
- 28 Dec 2022 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Metastatic disease) in Spain (IV)
- 20 May 2022 Phase-II clinical trials in Oesophageal cancer in China (IV) (Hinova Pharmaceuticals pipeline, May 2022)
- 20 May 2022 NMPA approves clinical trial application for AMC 303 in Oesophageal cancer before May 2022 (Hinova pharmaceuticals pipeline, May 2022)